Cargando…

Novel MRPS9-ALK Fusion Mutation in a Lung Adenocarcinoma Patient: A Case Report

Anaplastic lymphoma kinase (ALK) rearrangements account for approximately 5–6% of non–small-cell lung cancer (NSCLC) patients. In this study, a case of lung adenocarcinoma harboring a novel MRPS9-ALK fusion is reported. The patient responded well to the first and second generation of ALK-tyrosine ki...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhou, Huamiao, Xu, Binyue, Xu, Jili, Zhu, Guomeng, Guo, Yong
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217641/ https://www.ncbi.nlm.nih.gov/pubmed/34168990 http://dx.doi.org/10.3389/fonc.2021.670907

Ejemplares similares

Case Report: A Novel Non-Reciprocal ALK Fusion: ALK-GCA and EML4-ALK Were Identified in Lung Adenocarcinoma, Which May Respond to Alectinib Adjuvant-Targeted Therapy
por: Zhai, Xiaoqian, et al.
Publicado: (2022)

SMPD3‐ALK: A novel ALK fusion gene in lung adenocarcinoma
por: Liang, Yuepei, et al.
Publicado: (2021)

Concomitant EGFR Mutations and ALK Rearrangements in Lung Adenocarcinoma Treated With Osimertinib
por: Thomas, David, et al.
Publicado: (2023)

SDK1-ALK Fusion in a Lung Adenocarcinoma Patient With Excellent Response to ALK Inhibitor Treatment: A Case Report
por: Ma, Lin, et al.
Publicado: (2022)

LMO7-ALK Fusion in a Lung Adenocarcinoma Patient With Crizotinib: A Case Report
por: Yang, Yanlong, et al.
Publicado: (2022)

Case report: Complete pathological admission in N3 unresectable locally advanced lung adenocarcinoma with a novel INTS10-ALK and EML4-ALK fusion after neoadjuvant crizotinib
por: Zhai, Xiaoqian, et al.
Publicado: (2023)

Case Report: Identification of Two Rare Fusions, PDK1-ALK and STRN-ALK, That Coexist in a Lung Adenocarcinoma Patient and the Response to Alectinib
por: Zeng, Hao, et al.
Publicado: (2021)

A Novel Intergenic Gene Between SLC8A1 and PKDCC-ALK Fusion Responds to ALK TKI WX-0593 in Lung Adenocarcinoma: A Case Report
por: Du, Jia, et al.
Publicado: (2022)

Novel PPFIA1-ALK, ALK-C2orf91(intergenic) double-fusion responded well to alectinib in an advanced lung adenocarcinoma patient: a case report
por: Yan, Lingxin, et al.
Publicado: (2023)

Case report: Durable response to alectinib in ALK-rearranged lung adenocarcinoma with acquired, crizotinib-resistant ALK C1156F mutation
por: Rao, Chuangzhou, et al.
Publicado: (2022)

Stage IV EGFR Mutation-Negative and ALK Mutation-Negative Lung Adenocarcinoma: Long-Term Survival is Possible
por: Kedia, Shiksha, et al.
Publicado: (2015)

Lung adenocarcinoma patients with novel ALK fusion variants and their clinical responses to ALK inhibitors
por: Yang, Dafu, et al.
Publicado: (2021)

Secondary mutant ALK-I1171s in pituitary metastases from a patient with ALK fusion-positive advanced lung adenocarcinoma: A case report and literature review
por: Han, Dan, et al.
Publicado: (2022)

Coexistence of a novel STRN-ALK, NBEA-ALK double-fusion in an ovarian malignant mesothelioma patient: a case report and review
por: Wu, Xiao, et al.
Publicado: (2023)

Case Report: RAB10-ALK: A Novel ALK Fusion in a Patient With Gastric Cancer
por: Wen, Zhengqi, et al.
Publicado: (2021)

Acquired ALK G1202R-, ALK I1171N-, or EML4-ALK-mediated resistance to ensartinib in lung adenocarcinoma but responded to lorlatinib: A case report
por: Ye, Zhifeng, et al.
Publicado: (2023)

Monomerization of ALK Fusion Proteins as a Therapeutic Strategy in ALK-Rearranged Non-small Cell Lung Cancers
por: Hirai, Noriko, et al.
Publicado: (2020)

Complex ALK Fusions Are Associated With Better Prognosis in Advanced Non-Small Cell Lung Cancer
por: Kang, Jin, et al.
Publicado: (2020)

Fusion of EML4 and ALK is associated with development of lung adenocarcinomas lacking EGFR and KRAS mutations and is correlated with ALK expression
por: Zhang, Xuchao, et al.
Publicado: (2010)

Targeting SLMAP-ALK—a novel gene fusion in lung adenocarcinoma
por: Pagan, Carlos, et al.
Publicado: (2019)

Association of smoking and ALK tyrosine-kinase inhibitors on overall survival in treatment-naïve ALK-positive advanced lung adenocarcinoma
por: Zheng, Zhe-Rong, et al.
Publicado: (2023)

Novel NLRC4‐ALK and EML4‐ALK double fusion mutations in a lung adenocarcinoma patient: A case report
por: Wu, Xueqian, et al.
Publicado: (2020)

Clinical outcomes in ALK-rearranged lung adenocarcinomas according to ALK fusion variants
por: Cha, Yoon Jin, et al.
Publicado: (2016)

Case Report: A Pancreatic Ductal Adenocarcinoma Patient With Concurrent Targetable Somatic Novel KANK1-ALK, UPP2-NTRK3 Fusion, and Pathogenetic Germline BRCA Mutation
por: Meng, Fan, et al.
Publicado: (2021)

MRPS30-DT Knockdown Inhibits Breast Cancer Progression by Targeting Jab1/Cops5
por: Wu, Balu, et al.
Publicado: (2019)

ALK FISH patterns and the detection of ALK fusions by next generation sequencing in lung adenocarcinoma
por: Dacic, Sanja, et al.
Publicado: (2016)

Identification of a novel RMST-ALK rearrangement in advanced lung adenocarcinoma and durable response to ceritinib: A case report
por: Li, Hui, et al.
Publicado: (2022)

Case Report: ALK-Positive Histiocytosis With KIF5B-ALK Fusion in Cerebrum-Disseminated Lesions in a Child
por: Guo, Yi, et al.
Publicado: (2022)

A Screening Method for the ALK Fusion Gene in NSCLC
por: Murakami, Yoshiko, et al.
Publicado: (2012)

Case report: Dramatic response to alectinib in a lung adenosquamous carcinoma patient harbouring a novel CPE-ALK fusion
por: Qin, Yanyan, et al.
Publicado: (2022)

SEC31A-ALK Fusion Gene in Lung Adenocarcinoma
por: Kim, Ryong Nam, et al.
Publicado: (2016)

MRPS25 mutations impair mitochondrial translation and cause encephalomyopathy
por: Bugiardini, Enrico, et al.
Publicado: (2019)

A case of lung adenocarcinoma harboring EGFR mutation and EML4-ALK fusion gene
por: Tanaka, Hisashi, et al.
Publicado: (2012)

Case report: BRAF A598-T599insV mutation as a potential resistance mechanism to alectinib in ALK-rearranged lung adenocarcinoma
por: Pasau, Thomas, et al.
Publicado: (2022)

The Impact of Clinical Factors, ALK Fusion Variants, and BIM Polymorphism on Crizotinib-Treated Advanced EML4–ALK Rearranged Non-small Cell Lung Cancer
por: Lin, Yen-Ting, et al.
Publicado: (2019)

Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
por: Sweis, Randy F, et al.
Publicado: (2016)

TFG::ALK fusion in ALK positive large B-cell lymphoma: a case report and review of literature
por: Xiao, Andrew, et al.
Publicado: (2023)

Genomic Profiling Reveals Synchronous Bilateral Lung Adenocarcinomas With Distinct Driver Alterations of EML4-ALK or TPM3-ROS1 Fusion: A Case Report
por: Tan, Benxu, et al.
Publicado: (2019)

Novel ALK Fusion, PPFIBP1-ALK, in Pancreatic Ductal Adenocarcinoma Responsive to Alectinib and Lorlatinib
por: Gower, Arjan, et al.
Publicado: (2020)

ALK-R3HDM1 and EML4-ALK fusion as a mechanism of acquired resistance to gefitinib: A case report and literature review
por: Zeng, Zhu, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9o49ggu138u56p07vutav2t2lv